{"id":544612,"date":"2021-05-25T15:04:01","date_gmt":"2021-05-25T15:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544612"},"modified":"2021-05-25T15:04:01","modified_gmt":"2021-05-25T15:04:01","slug":"limb-girdle-muscular-dystrophy-lgmd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/limb-girdle-muscular-dystrophy-lgmd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544612.html","title":{"rendered":"Limb Girdle Muscular Dystrophy (LGMD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Limb<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Limb-Girdle Muscular Dystrophy (LGMD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Limb-Girdle Muscular Dystrophy (LGMD), historical and forecasted epidemiology as well as the Limb-Girdle Muscular Dystrophy (LGMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

DelveInsight has launched a new report on “Limb-Girdle Muscular Dystrophy (LGMD) -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Limb-Girdle Muscular Dystrophy (LGMD)  – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Limb-Girdle Muscular Dystrophy (LGMD) , historical and forecasted epidemiology as well as the  Limb-Girdle Muscular Dystrophy (LGMD)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to research, Limb-Girdle Muscular Dystrophy (LGMD) affects males and females in equal numbers. Estimates range the prevalence of LGMD from one in 14,500 to one in 123,000. The age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from population to population, but worldwide LGMD2G, 2H and 2J are extremely rare.<\/p>\n<\/li>\n

  2. \n

    According to a study, LGMD is the fourth most common muscular dystrophy, with a pooled prevalence of 1.63 per 100,000 people, following myotonic dystrophy, dystrophinopathy, and facioscapulohumeral dystrophy. The prevalence varies among subtypes and regions. <\/p>\n<\/li>\n

  3. \n

    According to the study, the estimated prevalence for all forms of LGMD ranges from 1\/44,000 to 1\/123,000. It is difficult to determine the prevalence of limb-girdle muscular dystrophy because its features vary and overlap with those of other muscle disorders.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Limb-Girdle Muscular Dystrophy (LGMD) market report covers a descriptive overview and comprehensive insight of the Limb-Girdle Muscular Dystrophy (LGMD)  epidemiology and Limb-Girdle Muscular Dystrophy (LGMD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Limb-Girdle Muscular Dystrophy (LGMD) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Limb-Girdle Muscular Dystrophy (LGMD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Limb-Girdle Muscular Dystrophy (LGMD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Limb-Girdle Muscular Dystrophy (LGMD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/limb-girdle-muscular-dystrophy-lgmd-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Limb-Girdle Muscular Dystrophy (LGMD): Overview<\/strong><\/p>\n

    Limb-girdle muscular dystrophies (LGMD) are a group of rare progressive genetic disorders that are characterized by wasting (atrophy) and weakness of the voluntary muscles of the hip and shoulder areas (limb-girdle area). Muscle weakness and atrophy are progressive and may spread to affect other muscles of the body.<\/p>\n

    The key players involved in the Limb-Girdle Muscular Dystrophy (LGMD) market:<\/strong><\/p>\n

      \n
    1. \n

      ML Bio Solutions,Inc.<\/p>\n<\/li>\n

    2. \n

      Sarepta Therapeutics, Inc.<\/p>\n<\/li>\n

    3. \n

      Catabasis Pharmaceuticals<\/p>\n<\/li>\n

    4. \n

      aTyr Pharma<\/p>\n<\/li>\n

    5. \n

      Sarepta Therapeutics, Inc<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Limb-Girdle Muscular Dystrophy (LGMD) treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        BBP-418<\/p>\n<\/li>\n

      2. \n

        SRP-9003 <\/p>\n<\/li>\n

      3. \n

        CAT-1004 <\/p>\n<\/li>\n

      4. \n

        ATYR1940<\/p>\n<\/li>\n

      5. \n

        SRP-9005  <\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/limb-girdle-muscular-dystrophy-lgmd-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Limb-Girdle Muscular Dystrophy (LGMD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Limb-Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance<\/p>\n

        6. Limb-Girdle Muscular Dystrophy (LGMD) Disease Background and Overview<\/p>\n

        7. Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Limb-Girdle Muscular Dystrophy (LGMD) <\/p>\n

        9. Limb-Girdle Muscular Dystrophy (LGMD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Limb-Girdle Muscular Dystrophy (LGMD) Emerging Therapies<\/p>\n

        12. Limb-Girdle Muscular Dystrophy (LGMD) Market Outlook<\/p>\n

        13. Country-Wise Limb-Girdle Muscular Dystrophy (LGMD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Limb-Girdle Muscular Dystrophy (LGMD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Limb-Girdle Muscular Dystrophy (LGMD)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Limb-Girdle Muscular Dystrophy (LGMD)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Limb-Girdle Muscular Dystrophy (LGMD) market. A detailed picture of the Limb-Girdle Muscular Dystrophy (LGMD) pipeline landscape is provided, which includes the disease overview and Limb-Girdle Muscular Dystrophy (LGMD) treatment guidelines.<\/p>\n

        Limb-Girdle Muscular Dystrophy (LGMD) -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Limb-Girdle Muscular Dystrophy (LGMD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Limb-Girdle Muscular Dystrophy (LGMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Limb-Girdle Muscular Dystrophy (LGMD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Limb-Girdle Muscular Dystrophy (LGMD), historical and forecasted epidemiology as well as the Limb-Girdle Muscular Dystrophy (LGMD) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544612","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544612"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544612\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}